JAGX Earnings Date & History
Jaguar Health Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:38 PM ET
Jaguar Health Inc
Pharmaceuticals
- Next earnings date
- Thursday, November 12, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-1.19
- Revenue estimate
- $4.9M
JAGX earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, May 20, 2026 | Q1 2026 | $-2.08 | $-13.60 | -553.6% | $20.3M |
| Tuesday, November 18, 2025 | Q3 2025 | $-181.36 | $-219.80 | -21.2% | $3.1M |
| Thursday, August 14, 2025 | Q2 2025 | $-254.54 | $-359.10 | -41.1% | $2.9M |
What the market is watching in JAGX's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next JAGX earnings date?
- Jaguar Health Inc is scheduled to report on Thursday, November 12, 2026 (Time TBD). Dates can change until the company confirms them.
- Does JAGX report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for JAGX?
- Consensus EPS for the upcoming quarter is $-1.19, on revenue of $4.9M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
JAGX earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.